Cargando…

An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer

The antiangiogenic effects of thalidomide have been assessed in clinical trials in patients with various solid and haematological malignancies. Thalidomide blocks the activity of angiogenic agents including bFGF, VEGF and IL-6. We undertook an open-label study using thalidomide 100 mg once daily for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drake, M J, Robson, W, Mehta, P, Schofield, I, Neal, D E, Leung, H Y
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377091/ https://www.ncbi.nlm.nih.gov/pubmed/12644816 http://dx.doi.org/10.1038/sj.bjc.6600817

Ejemplares similares

The efficacy and safety of docetaxel plus thalidomide vs. docetaxel alone in patients with androgen-independent prostate cancer: a systematic review
por: Chen, Long, et al.
Publicado: (2014)

Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma
por: Boyar, Michelle S., et al.
Publicado: (2008)

Mechanisms of Androgen-Independent Prostate Cancer
por: Saraon, Punit, et al.
Publicado: (2014)

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer
por: Eisen, T, et al.
Publicado: (2000)

An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
por: Tsuchiya, Tomohiro, et al.
Publicado: (2019)

A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer
por: Shamash, J, et al.
Publicado: (2008)

A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer
por: Gross, Mitchell, et al.
Publicado: (2007)

Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog–Thalidomide PROTACs
por: Kim, Ga Yeong, et al.
Publicado: (2021)

Is the Low-Thalidomide Dose MPT Regimen Beneficial?
por: Min, Chang-Ki
Publicado: (2011)

Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study
por: You, Dalsan, et al.
Publicado: (2015)

Arsenic and Prostate Cancer: Acquiring Androgen Independence
por: Tibbetts, John
Publicado: (2005)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer
por: Aggarwal, Rahul, et al.
Publicado: (2022)

Posttranslational regulation of androgen dependent and independent androgen receptor activities in prostate cancer
por: Wen, Simeng, et al.
Publicado: (2020)

Independence of HIF1a and androgen signaling pathways in prostate cancer
por: Tran, Maxine G. B., et al.
Publicado: (2020)

Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial
por: Ai, Xinghao, et al.
Publicado: (2021)

Intermittent chemotherapy in metastatic androgen-independent prostate cancer
por: Beer, T M, et al.
Publicado: (2003)

Thalidomide—Then and Now: Case Report of a Woman With Thalidomide Embryopathy and Review of Current Thalidomide Uses
por: Malik, Sara, et al.
Publicado: (2021)

Thalidomide induces clinical remission and mucosal healing in adults with active Crohn’s disease: a prospective open-label study
por: He, Yao, et al.
Publicado: (2017)

Regulation of expression of Na(+),K(+)-ATPase in androgen-dependent and androgen-independent prostate cancer
por: Blok, L J, et al.
Publicado: (1999)

Mechanism of Anti-Cancer Activity of Curcumin on Androgen-Dependent and Androgen-Independent Prostate Cancer
por: Abd. Wahab, Nurul Azwa, et al.
Publicado: (2020)

Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC)
por: Drake, Charles G, et al.
Publicado: (2015)

Rethinking thalidomide.
Publicado: (1995)

Thalidomide and neurotrophism
por: Soper, Judith R., et al.
Publicado: (2018)

Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial
por: Wester, Ruth, et al.
Publicado: (2019)

Anticancer Imidazoacridinone C-1311 is Effective in Androgen-Dependent and Androgen-Independent Prostate Cancer Cells
por: Niemira, Magdalena, et al.
Publicado: (2020)

Sulfur inhibits the growth of androgen-independent prostate cancer in vivo
por: DUAN, FEI, et al.
Publicado: (2015)

Mechanism of Androgen-Independent Stromal Proliferation in Benign Prostatic Hyperplasia
por: Hata, Junya, et al.
Publicado: (2023)

Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial
por: Zhao, Xianzhi, et al.
Publicado: (2022)

S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial
por: Chi, Yihebali, et al.
Publicado: (2022)

Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens
por: Dart, D. A., et al.
Publicado: (2011)

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects
por: Dredge, K, et al.
Publicado: (2002)

SHH-N non-canonically sustains androgen receptor activity in androgen-independent prostate cancer cells
por: Trnski, Diana, et al.
Publicado: (2021)

The treatment of advanced renal cell cancer with high-dose oral thalidomide
por: Stebbing, J, et al.
Publicado: (2001)

The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
por: Hashimoto, Shigeo, et al.
Publicado: (2016)

Thalidomide in Dermatology: Revisited
por: Hassan, Iffat, et al.
Publicado: (2015)

Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer
por: Beer, T M, et al.
Publicado: (2004)

Evolving perspectives of the role of novel agents in androgen-independent prostate cancer
por: Kalmadi, Sujith, et al.
Publicado: (2008)

Early Human Prostate Adenocarcinomas Harbor Androgen-Independent Cancer Cells
por: Fiñones, Rita R., et al.
Publicado: (2013)

Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer
por: Xu, Lingfan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7ri77as22hjk89of55r46bhhup